Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022.
Biotricity Inc. (Biotricity) today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022.
Biotricity Inc. (Biotricity) today announced that its Bioheart device has been named to TIME’s list of the Best Inventions of 2022. Bioheart is the first of its kind – a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights.
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced the U.S. launch of Biocare Cardiac. The national roll-out follows two successful pilot programs in Oklahoma City with CardioVascular Health Clinic, a medical facility providing high-quality cardiovascular care to more than 40,000 patients, and a four-month pilot with Lexington Heart Specialists in Kentucky, a medical practice providing high-quality cardiovascular care to more than 20,000 patients.
Biotricity Inc. (Biotricity) today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient’s ECG information, has captured billions of heartbeats to date, monitored in real-time by Bioflux’s built in algorithms, certified cardiac technicians and benchmarked by Artificial Intelligence (AI).
Biotricity Inc. (Biotricity), today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with Chronic Kidney Disease (‘CKD’). The risk of ischemic and hemorrhagic stroke is 5 to 30 times higher in patients with CKD and has a mortality rate of up to three times that of the general population. Effective stroke risk prediction is currently flawed in CKD patients because comorbidities often remain undiagnosed and stroke risk stratification schemes do not consider stages of CKD. Additionally, the detection of stroke-risk variations due to dialysis requires real-time risk monitoring, which is unavailable to date.
Biotricity Inc. (Biotricity) today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks.”
Biotricity Inc. (Biotricity) today announced its financial results for its fiscal 2022 fourth quarter and year ended March 31, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, “Fiscal 2022 was a pivotal year for Biotricity as we made significant strides in our product development and commercialization strategy.
Biotricity Inc. (Biotricity) today announced that the company is expected to join the Russell Microcap® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022. Membership in the Russell Microcap® Index, which remains in place for one year, includes inclusion in the appropriate growth and value style indexes.
Biotricity Inc. (Biotricity) today provided an update for its shareholders by Chief Executive Officer Waqaas Al-Siddiq, Ph.D., that discusses recent company achievements and strategic initiatives to position the business for strong 2022 results, increasing scale and accelerating growth into 2023.
Biotricity Inc. (Biotricity) will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022.
